{"name":"SDK Therapeutics, Inc.","slug":"sdk-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IV Arsenic Trioxide","genericName":"IV Arsenic Trioxide","slug":"iv-arsenic-trioxide","indication":"Acute promyelocytic leukemia (APL), newly diagnosed and relapsed/refractory","status":"phase_3"}]}],"pipeline":[{"name":"IV Arsenic Trioxide","genericName":"IV Arsenic Trioxide","slug":"iv-arsenic-trioxide","phase":"phase_3","mechanism":"Arsenic trioxide induces differentiation and apoptosis of leukemic cells, particularly in acute promyelocytic leukemia, through multiple pathways including PML-RARA degradation and reactive oxygen species generation.","indications":["Acute promyelocytic leukemia (APL), newly diagnosed and relapsed/refractory"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFBEX2p1ZFpCYktUMUFZQ1BlVExFejdnWjlVUm9NUDNwODhSM0FndThoMWpRc3BoTzI5V3djUmozc2pLU1hGTnVFNWlSZ1pDSTFnNng4MGotYXIzT1U?oc=5","date":"2025-02-10","type":"regulatory","source":"The University of Hong Kong (HKU)","summary":"FDA and EMA designations for HKUMed game-changing invention: Oral arsenic trioxide for leukaemia with a 97% cure rate First prescription medicine in Hong Kong to be globalised - All News - Media - The","headline":"FDA and EMA designations for HKUMed game-changing invention: Oral arsenic trioxide for leukaemia with a 97% cure rate Fi","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}